JP2011510995A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510995A5
JP2011510995A5 JP2010545168A JP2010545168A JP2011510995A5 JP 2011510995 A5 JP2011510995 A5 JP 2011510995A5 JP 2010545168 A JP2010545168 A JP 2010545168A JP 2010545168 A JP2010545168 A JP 2010545168A JP 2011510995 A5 JP2011510995 A5 JP 2011510995A5
Authority
JP
Japan
Prior art keywords
methyl
pyrazolo
indazol
pyrimidin
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010545168A
Other languages
English (en)
Japanese (ja)
Other versions
JP5608099B2 (ja
JP2011510995A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/032459 external-priority patent/WO2009097446A1/en
Publication of JP2011510995A publication Critical patent/JP2011510995A/ja
Publication of JP2011510995A5 publication Critical patent/JP2011510995A5/ja
Application granted granted Critical
Publication of JP5608099B2 publication Critical patent/JP5608099B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010545168A 2008-01-30 2009-01-29 ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法 Expired - Fee Related JP5608099B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2481308P 2008-01-30 2008-01-30
US61/024,813 2008-01-30
PCT/US2009/032459 WO2009097446A1 (en) 2008-01-30 2009-01-29 Pyrazolopyrimidine pi3k inhibitor compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2011510995A JP2011510995A (ja) 2011-04-07
JP2011510995A5 true JP2011510995A5 (enExample) 2012-03-22
JP5608099B2 JP5608099B2 (ja) 2014-10-15

Family

ID=40548738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010545168A Expired - Fee Related JP5608099B2 (ja) 2008-01-30 2009-01-29 ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法

Country Status (7)

Country Link
US (1) US8987280B2 (enExample)
EP (1) EP2252616B1 (enExample)
JP (1) JP5608099B2 (enExample)
CN (1) CN101981037B (enExample)
CA (1) CA2711759A1 (enExample)
ES (1) ES2494365T3 (enExample)
WO (1) WO2009097446A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
WO2010011620A1 (en) * 2008-07-21 2010-01-28 Wyeth 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8653098B2 (en) 2008-11-20 2014-02-18 Genentech, Inc. Pyrazolopyridine PI3K inhibitor compounds and methods of use
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
AU2010352577A1 (en) * 2010-05-05 2012-01-19 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as PKC-theta inhibitors
JP5894980B2 (ja) * 2010-05-24 2016-03-30 インテリカイン， エルエルシー 複素環式化合物およびその使用
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
MX2013000389A (es) * 2010-07-14 2013-03-08 Hoffmann La Roche Compuestos de purina selectivos para fosfatidilinositol 3-cinasa p110 delta, y metodods de uso.
EA026134B1 (ru) 2010-12-16 2017-03-31 Ф. Хоффманн-Ля Рош Аг Трициклические ингибиторы pi3k и способы их применения
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
MX389479B (es) 2011-09-02 2025-03-20 Incyte Holdings Corp Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k)
MX347765B (es) 2011-09-30 2017-05-12 Oncodesign Sa Inhibidores macrociclicos de la quinasa flt3.
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CN104350144B (zh) 2012-05-23 2017-08-04 弗·哈夫曼-拉罗切有限公司 获得和使用内胚层和肝细胞的组合物和方法
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA027752B1 (ru) * 2012-12-20 2017-08-31 Юсб Биофарма Спрл Терапевтически активные производные пиразолопиримидина
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
EP3079700B1 (en) 2013-12-11 2020-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2015088885A1 (en) * 2013-12-11 2015-06-18 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
PE20161475A1 (es) * 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG10201912302VA (en) 2015-02-27 2020-02-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN105037373B (zh) * 2015-07-13 2018-07-31 北京理工大学 一种合成吡唑并[3,4-d]嘧啶类化合物的方法
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3661919A4 (en) * 2017-08-02 2021-03-31 Northwestern University SUBSTITUTED FUSION PYRIMIDINE COMPOUNDS AND THEIR USES
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University COMBINATION THERAPY FOR A PI3K-ASSOCIATED DISEASE OR DISORDER
IL278889B2 (en) 2018-06-01 2025-11-01 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
US12054488B2 (en) * 2018-09-27 2024-08-06 Suzhou Raymon Pharmaceuticals Company, Ltd. Pyrazolopyrimidine compound and preparation method therefor and use thereof in preparation of anti-cancer drug
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3153096A1 (en) 2019-09-13 2021-03-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021133915A1 (en) * 2019-12-23 2021-07-01 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN116023380B (zh) * 2021-10-26 2024-01-23 沈阳药科大学 一类吡唑并嘧啶衍生物及制备方法和应用
WO2024249380A2 (en) * 2023-05-26 2024-12-05 University Of Vermont And State Agricultural College 1h-pyrazolo[3,4-d]pyrimidin-4-amines as anti-infectious agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR206F (enExample) * 1965-07-20
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
WO1999011643A1 (en) * 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
US7217710B2 (en) * 2001-10-02 2007-05-15 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
EP1608631A4 (en) * 2003-03-28 2008-08-20 Scios Inc BICYCLIC PYRIMIDININHIBITORS OF TGF BETA
AU2004293026B2 (en) * 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
JP2006056882A (ja) * 2004-07-23 2006-03-02 Tanabe Seiyaku Co Ltd ピラゾロピリミジン化合物
EP1772454A4 (en) * 2004-07-23 2009-02-25 Mitsubishi Tanabe Pharma Corp NITROGENIC CONDENSED BICYCLIC COMPOUND
JP2006056883A (ja) * 2004-07-23 2006-03-02 Tanabe Seiyaku Co Ltd 含窒素縮合二環式化合物およびその製法
KR20070058602A (ko) * 2004-09-30 2007-06-08 티보텍 파마슈티칼즈 리미티드 Ｈｃｖ 저해 바이-사이클릭 피리미딘
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
KR20070118068A (ko) * 2004-11-23 2007-12-13 레디 유에스 테라퓨틱스 인코포레이티드 신규의 이원 헤테로고리 화합물, 그 제조방법 및 이들을포함하는 조성물
AU2005322085B2 (en) * 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
GB0524436D0 (en) * 2005-11-30 2006-01-11 Novartis Ag Organic compounds
JP2007217408A (ja) * 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
KR101533461B1 (ko) * 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors

Similar Documents

Publication Publication Date Title
CN103124729B (zh) 作为Axl抑制剂的药物活性化合物
JP5597353B2 (ja) 置換ピラゾール化合物
JP6524221B2 (ja) Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物
CN116723843A (zh) 用于治疗和/或预防癌症的sos1抑制剂的药物组合
TWI629266B (zh) 纖維母細胞生長因子受體之抑制劑
KR101192939B1 (ko) 수용체 티로신 키나아제 저해제로서의 피라졸 유도체
US7582645B2 (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
TW202039489A (zh) Mat2a之雜雙環抑制劑及用於治療癌症之使用方法
KR100737259B1 (ko) 이미다조[1,2-ａ]피리딘 및 피라졸로[2,3-ａ]피리딘 유도체
JP2022531801A5 (enExample)
RU2008145662A (ru) Ингибиторы фосфоинозитид-3-киназы и содержащие их фармацевтические композиции
RU2009125897A (ru) Ингибиторы фосфоинозитид-3-киназы и способы их применения
JP2009535335A5 (enExample)
KR20090129434A (ko) 피리미딘-2,4-디아민 유도체 및 ｊａｋ2 키나제 억제제로서의 이의 용도
JP2010540458A5 (enExample)
JP2012512887A5 (enExample)
JP2010512337A5 (enExample)
JP2010512338A5 (enExample)
JP2011521968A5 (enExample)
CN106535890A (zh) 5‑取代的吲唑‑3‑羧酰胺及其制备和应用
US20050009845A1 (en) Thienopyrimidine compounds as protein tyrosine kinase inhibitors
JP2016513661A (ja) Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
KR20010050223A (ko) Ｃｒｆ 길항제 및 관련 조성물의 용도
RU2015148359A (ru) Хиназолины и азахиназолины - двойные ингибиторы путей ras/raf/mek/erk и pi3k/akt/pten/mtor
CZ304767B6 (cs) Substituovaný pyridin a pyridazin, farmaceutická kompozice s jeho obsahem a použití